FWFred Wamunyokoli

Fred Wamunyokoli

*This is an algorithmically generated author record based on publicly available information.

Fred Wamunyokoli has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Full-Genome Characterization of Hepatitis B Virus Among Asymptomatic Carriers in Kenya

    by Silvanos Opanda, George Gachara, Fred Wamunyokoli, Erick Kitangala, Kenfri Muchui, Timothy Mwasia, Maurice Wakwabubi, Wallace Bulimo

    Hepatitis B virus (HBV) infection remains a significant global public health concern. Data suggest that HBV genotypes/sub-genotypes and virulence-associated mutations can influence the natural history and treatment outcomes of HBV infection. However, the dearth of full-length HBV genome sequences in Kenya limits complete understanding of emerging variants and recombination events. Here, we sequenced and analyzed 165 HBV DNA whole-genome sequences from HBsAg-positive serum samples of voluntary blood donors across different geographic regions of Kenya between 2019 and 2023 to provide deeper insights into the virus’s genomic diversity, virulence-associated mutations, recombinations, and drug resistance profiles. Genomic analysis revealed a predominance of HBV genotype A in Kenya (77.0%), followed by genotype D (19.4%) and genotype E (3.6%) during the study period. Within genotype A, sub-genotype A1 predominated (99%), while A2 was a minority. Among genotype D, sub-genotype D7 was most common (97%), followed by D1 (3%). Recombination was detected in 4.2% of the sequenced isolates and involved genotype A/D, A/E, D/A, and D/E recombinant forms. None of the sequenced isolates harbored mutations linked to resistance to approved nucleos(t)ide analogues in the reverse transcriptase region of the polymerase gene. However, genetic variation associated with a higher risk of hepatocellular carcinoma (HCC), vaccine immune escape, and occult hepatitis B virus infection (OBI) were detected across genomic regions, including HCC-linked mutations G1896A in 81.3% (26/32; 95% CI: 63.6–92.8) of genotype D and 50% (3/6; 95% CI: 11.8–88.2) of genotype E isolates (FDR-adjusted p < 0.001); and G1899A in 17.0% (28/165; 95% CI: 11.6–23.6, FDR-adjusted p < 0.05) in the precore gene region of all isolates. Additionally, those present in the basal core promoter region included C1773T in 80.0% (132/165; 95% CI: 73.1–85.8, FDR-adjusted p < 0.001) and A1762T/G1764-double mutation in 29.1% (48/165; 95% CI: 22.3–36.7) of all isolates. Immune escape-linked amino acid variation within the “a” determinant of the major hydrophilic region (MHR) in the S gene region, included T131N in 99.2% (126/127; 95% CI: 95.7–100, FDR-adjusted p < 0.001) of genotype A and T126A/S in 16.7% (1/6; 95% CI, 0.4–64.1, FDR-adjusted p > 0.05) of genotype E isolates, while those related to occult-HBV infection (OBI) included P127H/L in 3.6% (6/165; 1.3–7.7, FDR-adjusted p < 0.001) of all isolates. Overall, our findings indicate that HBV genotype A (sub-genotype A1) predominates in Kenya, followed by genotypes D (sub-genotype D7) and E. Moreover, the detection of HBV variants harboring genetic markers associated with immune escape, occult hepatitis B (OBI), and liver disease complications highlights the need for public health countermeasures such as immunization of infants and scaling up of adult vaccination to reduce infections. Furthermore, wider integration of molecular real-time PCR testing into the national blood screening algorithm is advised to reduce the risk of horizontal transmission from asymptomatic HBV blood donors harboring occult HBV infection mutations and ensure the safety of blood and blood products.

  • Open Access

    Evidence of reduced treatment adherence among HIV infected paediatric and adolescent populations in Nairobi at the onset of the UNAIDS Universal Test and Treat Program

    by Joseph Kabogo, Erastus Muniu, Fred Wamunyokoli, Rachel Musoke, Elijah Songok

    We conducted a retrospective cohort study to evaluate the efficacy of the World Health Organization (WHO) “Universal Test and Treat” (UTT) policy, initiated in Kenya in September 2016. Under this policy, every human immunodeficiency virus (HIV)-infected person should be initiated on antiretroviral therapy (ART). We compared intra- and inter-group viral suppression and ART adherence rates for pre-UTT (initiated on ART in March–August 2016) and UTT groups (initiated in September 2016). The study was conducted in a community outreach Program in Nairobi with 3500 HIV-infected children enrolled. 122 children and adolescents were initiated on first-line ART pre-UTT, and 197 during the UTT period. The 6 month viral suppression rate was 79.7% pre-UTT versus 76.6% UTT (P < 0.05). Suboptimal adherence was higher in the UTT than pre-UTT period (88 of 197, 44.7% and 44 of 122, 34%; P < 0.001). The decrease in adherence was greater among orphans (91.7% pre-UTT and 87.2% UTT, P = 0.001) and children 11–18 years. Our results show that successful implementation of the UTT policy in Africa is challenged by an increased risk of suboptimal adherence. There is a need to develop extra strategies to support adherence, especially among orphans and teenagers.


  • Open Access

    Genotyping of enteroviruses isolated in Kenya from pediatric patients using partial VP1 region

    by Silvanos M. Opanda, Fred Wamunyokoli, Samoel Khamadi, Rodney Coldren, Wallace D. Bulimo

    Enteroviruses (EV) are responsible for a wide range of clinical diseases in humans. Though studied broadly in several regions of the world, the genetic diversity of human enteroviruses (HEV) circulating in the sub-Saharan Africa remains under-documented. In the current study, we molecularly typed 61 HEV strains isolated in Kenya between 2008 and 2011 targeting the 3′-end of the VP1 gene. Viral RNA was extracted from the archived isolates and part of the VP1 gene amplified by RT-PCR, followed by sequence analysis. Twenty-two different EV types were detected. Majority (72.0 %) of these belonged to Enterovirus B species followed by Enterovirus D (21.3 %) and Enterovirus A (6.5 %). The most frequently detected types were Enterovirus-D68 (EV-D68), followed by Coxsackievirus B2 (CV-B2), CV-B1, CV-B4 and CV-B3. Phylogenetic analyses of these viruses revealed that Kenyan CV-B1 isolates were segregated among sequences of global CV-B1 strains. Conversely, the Kenyan CV-B2, CV-B3, CV-B4 and EV-D68 strains generally grouped together with those detected from other countries. Notably, the Kenyan EV-D68 strains largely clustered with sequences of global strains obtained between 2008 and 2010 than those circulating in recent years. Overall, our results indicate that HEV strains belonging to Enterovirus D and Enterovirus B species pre-dominantly circulated and played a significant role in pediatric respiratory infection in Kenya, during the study period. The Kenyan CV-B1 strains were genetically divergent from those circulating in other countries. Phylogenetic clustering of Kenyan EV-D68 strains with sequences of global strains circulating between 2008 and 2010 than those obtained in recent years suggests a high genomic variability associated with the surface protein encoding VP1 gene in these enteroviruses.


  • Molecular characterization of human parainfluenza virus type 1 in infants attending Mbagathi District Hospital, Nairobi, Kenya: a retrospective study

    by Joshua K. Kiptinness, Eyako K. Wurapa, Fred Wamunyokoli, Wallace D. Bulimo

    Human parainfluenza virus type 1 (HPIV-1), a paramyxovirus, is a leading cause of pediatric respiratory hospitalizations globally. Currently, there is no clinically successful vaccine against HPIV-1. Hence, there is a need to characterize circulating strains of this virus to establish the feasibility of developing a vaccine against the virus. The variable HPIV-1 hemagglutin–neuraminidase (HN) protein is found in the envelope of HPIV-1, where it initiates the infection process by binding to cellular receptors. HN is also the major antigen against which the human immune response is directed against. The present study focused on identifying mutations in the HN gene that would be useful in understanding the evolution of HPIV-1. 21 HPIV-1 isolates were obtained after screening nasopharyngeal samples from patients with influenza-like illness. The samples were collected from Mbagathi District Hospital Nairobi from the period July 2007 to December 2010. RT-PCR was carried out on the isolates using HN-specific primers to amplify a 360 nt in the most polymorphic region and the amplicons sequenced. Genomic data were analysed using a suite of bioinformatic software. Forty eight polymorphic sites with a total of 55 mutations were identified at the nucleotide level and 47 mutations at 23 positions at the amino acid level. There was more radical nonsynonymous amino acid changes (seven positions) observed than conservative nonsynonymous changes (one position) on the HN gene fragment. No positively selected sites were found in the HN protein. The result from the analysis of 21 HPIV-1 Mbagathi isolates demonstrated that the HN gene which is the major antigenic target was under purifying (negative) selection displaying evolutionary stasis.